Wet Age-related macular degeneration

Common Name(s)

Wet Age-related macular degeneration

Wet macular degeneration, or exudative macular degeneration, is an advanced form of age-related macular degeneration (AMD) which causes vision loss that gets worse over time (progressive). The macula is located in the central part of the back of the eye (retina) and helps a person see fine details and perform tasks such as reading and driving (sharp central vision). In all forms of AMD, damage to the macula leads to blurred or complete loss of central vision. In wet macular degeneration, abnormal blood vessels grow underneath the affected area of the macula (neovascularization). These new vessels are weak and leak blood and other important fluids. The affected areas then scar and affect vision.

Vision loss in wet macular degeneration is usually severe and rapid and only affects central vision, so affected people usually have normal vision on the edges of their eye (peripheral vision). Wet macular degeneration is the least common form of AMD, causing only 10 percent of all cases. Wet AMD typically starts off as dry macular degeneration, and then progresses to the more severe state.

The cause of wet macular degeneration is unclear. Age and genetics are the two most significant risk factors. Wet macular degeneration is usually found in adults over 55, and the risk increases with age. Smoking can also significantly increase the risk of developing the disorder. The condition is usually diagnosed by an eye doctor (ophthalmologist) who uses both a routine eye exam and special eye tests, such as optical coherence tomography (OCT), to look at images of the retina. There is no cure for wet macular degeneration, but good nutrition and protection from UV rays can help prevent symptoms. There are also medications available to help decrease or stop the formation of new blood vessels behind the macula. If you or a loved one has been diagnosed with AMD, talk to a doctor about all treatment options. Support groups can provide additional information.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Wet Age-related macular degeneration" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Wet Age-related macular degeneration" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Wet Age-related macular degeneration" returned 47 free, full-text research articles on human participants. First 3 results:

Comparison of macular pigment optical density in patients with dry and wet age-related macular degeneration.
 

Author(s): Ayhan Ozyurt, Nilufer Kocak, Pınar Akan, Ozlem Gursoy Calan, Taylan Ozturk, Mahmut Kaya, Eyup Karahan, Suleyman Kaynak

Journal: Indian J Ophthalmol. 2017 Jun;65(6):477-481.

 

The aim of the study was to evaluate the macular pigment optical density (MPOD) levels in patients with wet age-related macular degeneration (AMD), dry AMD, and also in healthy controls.

Last Updated: 23 Jun 2017

Go To URL
Long-term results after limited macular translocation surgery for wet age-related macular degeneration.
 

Author(s): Hisaaki Oshima, Takeshi Iwase, Kohei Ishikawa, Kentaro Yamamoto, Hiroko Terasaki

Journal:

 

To evaluate the long-term results of limited macular translocation (LMT) surgery with radial chorioscleral outfolding in patients with wet age-related macular degeneration (AMD) and subfoveal choroidal neovascularization (CNV). In addition, to identify the factors associated with ...

Last Updated: 25 May 2017

Go To URL
24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
 

Author(s): Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T Tsaousis

Journal:

 

To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of treatment.

Last Updated: 28 Apr 2017

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Wet Age-related macular degeneration" returned 6 free, full-text review articles on human participants. First 3 results:

Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts.
 

Author(s): Sofia Androudi, Anna Dastiridou, Nikolaos Pharmakakis, Maria Stefaniotou, Christos Kalogeropoulos, Chrysanthos Symeonidis, Alexandros Charonis, Miltiadis Tsilimbaris

Journal: Adv Ther. 2016 May;33(5):715-26.

 

To propose guidelines for the management of patients with wet age-related macular degeneration (wAMD), taking into account the results of large multicenter studies and clinical experience of retina experts.

Last Updated: 27 May 2016

Go To URL
Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
 

Author(s): Jun Ba, Run-Sheng Peng, Ding Xu, Yan-Hong Li, Hui Shi, Qianyi Wang, Jing Yu

Journal:

 

Age-related macular degeneration (AMD) is the main cause of blindness. Anti-vascular endothelial growth factor is used to prevent further neovascularization due to wet AMD. The purpose of this systematic review was to investigate the effect and protocol of anti-vascular endothelial ...

Last Updated: 9 Oct 2015

Go To URL
The treatment of wet age-related macular degeneration.
 

Author(s): Antonia M Joussen, Norbert Bornfeld

Journal: Dtsch Arztebl Int. 2009 May;106(18):312-7.

 

Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the area of the retina that has the highest visual acuity. It can progress to geographic atrophy or choroidal neovascularization.

Last Updated: 23 Jun 2009

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Time to Treatment Utilizing a Tele-Retinal Referral System for Wet Age Related Macular Degeneration and Diabetic Macular Edema: A Pilot Study
 

Status: Recruiting

Condition Summary: Wet Age Related Macular Degeneration; Diabetic Macular Edema

 

Last Updated: 14 Mar 2016

Go to URL
Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
 

Status: Recruiting

Condition Summary: Wet Age-related Macular Degeneration

 

Last Updated: 20 Oct 2017

Go to URL